What this trial means for you
This study is opening soon at 24 US sites. It's studying NNC0662-0419, Semaglutide, NNC0662-0419 Placebo, Semaglutide placebo for obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.
Study sites by state
Alabama
- Chambliss Clinical Trials, LLC — Montgomery
California
- FDRC — Costa Mesa
- Los Angeles Institute for Metabolic Research — Los Angeles
Florida
- Encore Medical Research LLC — Hollywood
- South Broward Research LLC — Miramar
- West Orange Endocrinology — Ocoee
Illinois
- Cedar-Crosse Research Center — Chicago
- Great Lakes Clinical Trials — Chicago
Indiana
- Midwest Inst For Clin Res — Indianapolis
Kentucky
- L-MARC Research Center — Louisville
Maryland
- Endo And Metab Cons — Rockville
Missouri
- StudyMetrix Research LLC — City of Saint Peters
New York
- Great Lakes Medical Research — Westfield
North Carolina
- KDCILM, LLC & Accellacare US, Inc. — Wilmington
Ohio
- Family Practice Center of Wadsworth Inc. — Wadsworth
Pennsylvania
- UPA Ctr Weight and Eating Dis — Philadelphia
Rhode Island
- Clinical Res Collaborative — Cumberland
Tennessee
- Holston Medical Group_Bristol — Bristol
- Holston Medical Group — Kingsport
- Clinical Research Associates — Nashville
Texas
- PlanIt Research, PLLC — Houston
- Pinnacle Clinical Research — San Antonio
Virginia
- National Clin Res Inc. — Richmond
Washington
- Rainier Clin Res Ctr Inc — Renton
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)